賴明陽
兼任教授
 
個人學經歷
 
學歷:

• 1964~1971 國立台灣大學醫學院醫科醫學士
• 1978~1984 國立台灣大學醫學院臨床醫學研究所博士

現任:
• 1980-迄今 國立台灣大學醫學院附設醫院內科主治醫師
• 1997-迄今 國立台灣大學醫學院臨床醫學研究所教授

經歷:
• 1972~1975 國立台灣大學醫學院附設醫院內科住院醫師
• 1975~1976 國立台灣大學醫學院附設醫院內科總住院醫師
• 1976~1980 國立台灣大學醫學院內科兼任講師
• 1980~1984 國立台灣大學醫學院內科講師
• 1984~1991 國立台灣大學醫學院臨床醫學研究所副教授
• 1998~2001 國立台灣大學醫學院附設醫院臨床醫學研究部主治醫師兼副主任
• 2000~2001 國立台灣大學醫學院附設醫院臨床醫學研究部代理主任
 
研究專長
 
Hepatology, Hepatitis B virus and hepatitis C virus. Clinical and basic studies, Molecular mechanism
實驗室可提供學習之技術:
1.Molecular biology techniques.
2.Cell culture.

 
五年內著作
 
1.Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004; 72:363-369.
2.Liu CJ, Kao JH, Lai MY, Chen PJ, Chen DS. Precore/Core promoter mutations and genotypes of hepatitis B virus in chronic hepatitis B patients with fulminant or subfulminant hepatitis. J Med Virol 2004; 72: 545-550.
3.Machida K, Cheng KTN, Sung VMH, Shimodaira S, Lindsay KL, Levine AM, Lai MY, Lai MMC. Hepatitis C virus induces a mutator phenotype : Enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U. S. A. 2004; 101: 4262-4267.
4.Chen JD, Liu CJ, Lee PH, Chen PJ, Lai MY, Kao JH, Chen DS. Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2004; 2: 64-71.
5.Lin CL, Liao LY, Wang CS, Chen PJ, Lai MY, Chen DS, Kao JH. Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy. Liver Int 2004; 24: 9-15.
6.Chang CY, Wang HP, Mao TL, Hu RH, Yang PM, Lai MY, Lin JT. Unusual sonographic appearance of a gastrointestinal stromal tumor presenting as a large multilocular cystic mass. J Clin Ultrasound 2004; 32(4): 200-203.
7.Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
8.Liu CJ, Kao JH, Wang HY, Lai MY, Chen TC, Chen PJ, Chen DS. Origin of serum hepatitis B virus in acute exacerbation : comparison with HBV in the liver and from other exacerbation. Hepatology 2004; 40: 310-317.
9.Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, Trejo-Estrada R, Horta E Vale A, Wintfeld N, Green J. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40:675-681.
10.Liu CJ, Chen PJ, Lai MY, Kao JH, Chen DS. Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion. J Med Virol 2004; 74:237-245.
11.Yeh SH, Lin MW, Lu SF, Wu DC, Tsai SF, Tsai CY, Lai MY, Hsu HC, Chen DS, Chen PJ. Allelic loss of chromosome 4q21 approximately 23 associates with hepatitis B virus-related hepatocarcinogenesis and elevated alpha-fetoprotein. Hepatology 2004; 40:847-854. 6
12.Liu CJ, Huang WL, Chen PJ, Lai MY, Kao JH, Chen DS. End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. World J Gastroenterol 2004; 10:3574-3578.
13.Wu YM, Ho MC, Hu RH, Ko WJ, Yang PM, Lai MY, Lee PH. Liver transplantation for acute hepatic failure. Transplant Proc 2004; 36:2226-2227.
14.Ho MC, Wu YM, Hu RH, Ko WJ, Ni YH, Chang MH, Yang PM, Lai MY, Lin MH, Lin HY, Lee PH. Surgical complications and outcome of living related liver transplantation. Transplant Proc 2004; 36:2249-2251.
15.Ho MC, Wu YM, Hu RH, Ko WJ, Yang PM, Lai MY, Lin MH, Lin HY, Lee PH. Liver transplantation for patients with hepatocellular carcinoma. Transplant Proc 2004; 36:2291-2292.
16.Wang SS, Chou NK, Ko WJ, Yu HY, Chen YS, Hsu RB, Huang SC, Chi NH, Tsao CI, Lai MY, Liau CS, Lee YT. Heart transplantation using donors positive for hepatitis. Transplant Proc 2004; 36:2371-2373.
17.Liu CJ, Chen PJ, Lai MY, Chen TC, Wang HY, Huang WL, Kao JH, Chen DS. Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba. Antivir Ther 2004; 9:895-903.
18.Mah YH, Kao JH, Liu CJ, Chen CL, Chen PJ, Lai MY, Chen DS. Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan. Liver Int 2005; 25:214-219.
19.Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, Chang WY, Chang TT, Hsieh TY, Liu CJ, Chen DS. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005; 12:283-291.
20.Lin CL, Liao LY, Wang CS, Chen PJ, Lai MY, Chen DS, Kao JH. Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver Int 2005; 25:564-570.
21.Liu CJ, Jeng YM, Chen PJ, Lai MY, Yang HC, Huang WL, Kao JH, Chen DS. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver 7 disease in chronic hepatitis C. Antivir Ther 2005; 10:405-415.
22.Hsieh TH, Kao JH, Lai MY, Chen PJ, Chen DS. Successful treatment with peginterferon and ribavirin in a patient with acute hepatitis C evolving into chronicity. J Formos Med Assoc 2005; 104:354-358.
23.Liu CJ, Chen PJ, Jeng YM, Huang WL, Yang WS, Lai MY, Kao JH, Chen DS. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 2005; 43:235-242.
24.Huang GT, Lee PH, Tsang YM, Lai MY, Yang PM, Hu RH, Chen PJ, Kao JH, Sheu JC, Lee CZ, Chen DS. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 2005; 242:36-42.
25.Lu JY, Chuang LM, Yang WS, Tai TY, Lai MY, Chen PJ, Kao JH, Lee CZ, Lee HS: Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. Liver Int 2005; 25:752-759.
26.Liu CJ, Chen PJ, Lai MY, Chen TC, Wang HY, Huang WL, Kao JH, Chen DS. Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba. Antivir Ther 2004; 9:895-903.
27.Lin CL, Kao JH, Chen BF, Chen PJ, Lai MY, Chen DS. Application of hepatitis B virus genotyping and phylogenetic analysis in intrafamilial transmission of hepatitis B virus. Clin Infect Dis 2005; 41:1576-1581.
28.Liu CJ, Kao JH, Chen PJ, Chen TC, Lin FY, Lai MY*, Chen DS. Overlap Lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. J Viral Hepat 2006; 13:387-395.
29.Liu CJ, Lo SC, Kao JH, Tseng PT, Lai MY, Ni YH, Yeh SH, Chen PJ, Chen DS. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol 2006; 44:39-46.
30.Lai MY. Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan. Intervirology 2006; 49:91-95. 8
31.Su DH, Lai MY, Wu HP. Liver failure in a patient receiving rosiglitazone therapy. Diabet Med 2006; 23:105-106.
32.Liu CH, Chen BF, Chen SC, Lai MY, Kao JH, Chen DS. Selective transmission of hepatitis C virus quasi species through a needlestick accident in acute resolving hepatitis. Clin Infect Dis 2006; 42:1254-1259.
33.Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, Chen DS. Role of hepatitis B viral load and Basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006; 193:1258-1265.
34.Liu CJ, Lai MY, Chao YC, Liao LY, Yang SS, Hsiao TJ, Hsieh TY, Lin CL, Hu JT, Chen CL, Chen PJ, Kao JH, Chen DS. Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. Hepatology 2006; 43:742-749.
35.Huang YW, Lin CL, Chen PJ, Lai MY, Kao JH, Chen DS. Higher cut-off index value of immunoglobulin M antibody to hepatitis B core antigen in Taiwanese patients with hepatitis B. J Gastroenterol Hepatol 2006; 21:859-862.
36.Hwang Y, Chen EY, Gu ZJ, Chuang WL, Yu ML, Lai MY, Chao YC, Lee CM, Wang JH, Dai CY, Shian-Jy Bey M, Liao YT, Chen PJ, Chen DS. Genetic predisposition of responsiveness to therapy for chronic hepatitis C. Pharmacogenomics 2006; 7:697-709.
37.Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, Chen DS. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis 2006; 194:594-599.
38.Chen CH, Huang GT, Yang PM, Chen PJ, Lai MY, Chen DS, Wang JD, Sheu JC. Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur J Cancer 2006; 42:2524-2529.
39.Liu CJ, Chen PJ, Lai MY, Lin FY, Wang T, Kao JH, Chen DS. Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B. Liver Int 2006; 26:949-955.
40.Wang SS, Chou NK, Chi NH, Hsu RB, Huang SC, Chen YS, Yu HY, Tsao CI, Ko WJ, Lai MY, Chu SH. Successful treatment of hepatitis B virus infection with Lamivudine after 9 heart transplantation. Transplant Proc 2006; 38:2138-2140.
41.Liu CH, Lin JW, Tsai FC, Yang PM, Lai MY, Chen JH, Kao JH, Chen DS. Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver Int 2006; 26:1087-1094.
42.Huang YW, Liu CJ, Lai MY*, Lee PH, Tsai MK, Wang SS, Lai MK, Kao JH. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series. Clin Ther 2006; 28:1327-1334.
43.Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto M, Farci P, Popescu M, McCloud P. Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56:699-705.
44.Wang CC, Liu CJ, Lai MY, Kao JH, Chen DS. Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients. Liver Int 2007; 27:235-239.
45.Tsai FC, Liu CJ, Chen CL, Chen PJ, Lai MY, Kao JH, Chen DS. Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma. J Viral Hepat 2007; 14:153-160.
46.Lin CL, Chen JD, Liu CJ, Lee PH, Chen PJ, Lai MY, Kao JH, Chen DS. Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma. J Viral Hepat 2007; 14:64-69.
47.Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jafri W, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22:615-633.
48.Lin CL, Liao LY, Liu CJ, Yu MW, Chen PJ, Lai MY, Chen DS, Kao JH. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology 2007; 45:1193-1198. 10
49.Liu WL, Su WC, Cheng CW, Hwang LH, Wang CC, Chen HL, Chen DS, Lai MY*. Ribavirin Up-Regulates the Activity of Double-Stranded RNA-Activated Protein Kinase and Enhances the Action of Interferon- alpha against Hepatitis C Virus. J Infect Dis 2007; 196:425-434.
50.Lin CL, Liu CH, Chen W, Huang WL, Chen PJ, Lai MY, Chen DS, Kao JH. Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22:1098-1103.
51.Hsu CS, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS. Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. Intervirology 2007; 50:310-315.
52.Tseng TC, Liu CJ, Chen PJ, Lai MY, Lin CL, Kao JH, Chen DS. Subgenotypes of hepatitis B virus genotype C do not correlate with disease progression of chronic hepatitis B in Taiwan. Liver Int 2007; 27:983-988.
53.Lin CL, Liu CJ, Chen PJ, Lai MY, Chen DS, Kao JH. High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users. J Med Virol 2007; 79:1674-1678.
54.Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, Hung PH, Liu CJ, Lai MY, Chen JH, Chen PJ, Kao JH, Chen DS. Pegylated Interferon Alfa-2a versus Standard Interferon Alfa-2a for Treatment-Naive Dialysis Patients with Chronic Hepatitis C: A Randomized Study. Gut 2007 Sep 19; (Epub ahead of print)
55.Liu CH, Hsu SJ, Lin JW, Hwang JJ, Liu CJ, Yang PM, Lai MY, Chen PJ, Chen JH, Kao JH, Chen DS. Noninvasive diagnosis of hepatic fibrosis in patients with chronic hepatitis C by splenic Doppler impedance index. Clin Gastroenterol Hepatol 2007; 5:1199-1206.
56.Hsu CS, Liu CJ, Liu CH, Wang CC, Chen CL, Lai MY, Chen PJ, Kao JH, Chen DS. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2007 Nov 19; (Epub ahead of print)
 
BACK